RHHBY Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -- compared to Roche Holding AG's net margin of 17.96%. Roche Holding AG's return on equity of 28.65% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Roche Holding AG has a consensus price target of $52.84, signalling upside risk potential of 0.6%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $55.09 which suggests that it could grow by 0.41%. Given that Roche Holding AG has higher upside potential than Bristol Myers Squibb Co., analysts believe Roche Holding AG is more attractive than Bristol Myers Squibb Co..

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.64%. Bristol Myers Squibb Co. offers a yield of 4.54% to investors and pays a quarterly dividend of $0.62 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Roche Holding AG's net income of -- is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Roche Holding AG's price-to-earnings ratio is 30.92x while Bristol Myers Squibb Co.'s PE ratio is 18.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.75x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Roche Holding AG's net margin of 31.72%. Roche Holding AG's return on equity of 28.65% beat Eli Lilly & Co.'s return on equity of 106.26%.

Roche Holding AG has a consensus price target of $52.84, signalling upside risk potential of 0.6%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.51%. Given that Eli Lilly & Co. has higher upside potential than Roche Holding AG, analysts believe Eli Lilly & Co. is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.64%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Roche Holding AG's net income of -- is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Roche Holding AG's price-to-earnings ratio is 30.92x while Eli Lilly & Co.'s PE ratio is 53.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.75x versus 16.52x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 28.26%. Roche Holding AG's return on equity of 28.65% beat Novartis AG's return on equity of 33.87%.

Roche Holding AG has a consensus price target of $52.84, signalling upside risk potential of 0.6%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could fall by -2.88%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.64%. Novartis AG offers a yield of 2.88% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.9B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $3.9B. Notably, Roche Holding AG's price-to-earnings ratio is 30.92x while Novartis AG's PE ratio is 18.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.75x versus 5.03x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Roche Holding AG's net margin of 21.32%. Roche Holding AG's return on equity of 28.65% beat Pfizer Inc.'s return on equity of 10.84%.

Roche Holding AG has a consensus price target of $52.84, signalling upside risk potential of 0.6%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Pfizer Inc. has higher upside potential than Roche Holding AG, analysts believe Pfizer Inc. is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.64%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Roche Holding AG quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Roche Holding AG's net income of -- is lower than Pfizer Inc.'s net income of $3.6B. Notably, Roche Holding AG's price-to-earnings ratio is 30.92x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.75x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.